360 related articles for article (PubMed ID: 12370275)
1. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
Schuff KG; Hentges ST; Kelly MA; Binart N; Kelly PA; Iuvone PM; Asa SL; Low MJ
J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
[TBL] [Abstract][Full Text] [Related]
2. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.
Asa SL; Kelly MA; Grandy DK; Low MJ
Endocrinology; 1999 Nov; 140(11):5348-55. PubMed ID: 10537166
[TBL] [Abstract][Full Text] [Related]
3. Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice.
Hentges ST; Low MJ
Endocrinology; 2002 Dec; 143(12):4536-43. PubMed ID: 12446580
[TBL] [Abstract][Full Text] [Related]
4. Autocrine actions of prolactin contribute to the regulation of lactotroph function in vivo.
Bernard V; Lamothe S; Beau I; Guillou A; Martin A; Le Tissier P; Grattan D; Young J; Binart N
FASEB J; 2018 Sep; 32(9):4791-4797. PubMed ID: 29596024
[TBL] [Abstract][Full Text] [Related]
5. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
Ben-Shlomo A; Miklovsky I; Ren SG; Yong WH; Heaney AP; Culler MD; Melmed S
J Clin Endocrinol Metab; 2003 Feb; 88(2):858-63. PubMed ID: 12574225
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
7. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.
McAndrew J; Paterson AJ; Asa SL; McCarthy KJ; Kudlow JE
Endocrinology; 1995 Oct; 136(10):4479-88. PubMed ID: 7664668
[TBL] [Abstract][Full Text] [Related]
8. Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.
Radl D; De Mei C; Chen E; Lee H; Borrelli E
Mol Endocrinol; 2013 Jun; 27(6):953-65. PubMed ID: 23608643
[TBL] [Abstract][Full Text] [Related]
9. Assessment of lactotroph axis functionality in mice: longitudinal monitoring of PRL secretion by ultrasensitive-ELISA.
Guillou A; Romanò N; Steyn F; Abitbol K; Le Tissier P; Bonnefont X; Chen C; Mollard P; Martin AO
Endocrinology; 2015 May; 156(5):1924-30. PubMed ID: 25643154
[TBL] [Abstract][Full Text] [Related]
10. Active and total transforming growth factor-β1 are differentially regulated by dopamine and estradiol in the pituitary.
Recouvreux MV; Guida MC; Rifkin DB; Becu-Villalobos D; Díaz-Torga G
Endocrinology; 2011 Jul; 152(7):2722-30. PubMed ID: 21521749
[TBL] [Abstract][Full Text] [Related]
11. Normal structural dopamine type 2 receptor gene in prolactin-secreting and other pituitary tumors.
Friedman E; Adams EF; Höög A; Gejman PV; Carson E; Larsson C; De Marco L; Werner S; Fahlbusch R; Nordenskjöld M
J Clin Endocrinol Metab; 1994 Mar; 78(3):568-74. PubMed ID: 7907340
[TBL] [Abstract][Full Text] [Related]
12. Pituitary hormone gene expression and secretion in human growth hormone-releasing hormone transgenic mice: focus on lactotroph function.
Moore JP; Cai A; Hostettler ME; Arbogast LA; Voogt JL; Hyde JF
Endocrinology; 2000 Jan; 141(1):81-90. PubMed ID: 10614626
[TBL] [Abstract][Full Text] [Related]
13. mPRs represent a novel target for PRL inhibition in experimental prolactinomas.
Camilletti MA; Abeledo-Machado A; Perez PA; Faraoni EY; De Fino F; Rulli SB; Ferraris J; Pisera D; Gutierrez S; Thomas P; Díaz-Torga G
Endocr Relat Cancer; 2019 May; 26(5):497-510. PubMed ID: 30856609
[TBL] [Abstract][Full Text] [Related]
14. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
15. Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?
Ferraris J
Front Endocrinol (Lausanne); 2022; 13():1057749. PubMed ID: 36714572
[TBL] [Abstract][Full Text] [Related]
16. Conditional Deletion of the Prolactin Receptor Reveals Functional Subpopulations of Dopamine Neurons in the Arcuate Nucleus of the Hypothalamus.
Brown RS; Kokay IC; Phillipps HR; Yip SH; Gustafson P; Wyatt A; Larsen CM; Knowles P; Ladyman SR; LeTissier P; Grattan DR
J Neurosci; 2016 Aug; 36(35):9173-85. PubMed ID: 27581458
[TBL] [Abstract][Full Text] [Related]
17. Fetal Alcohol Exposure Reduces Dopamine Receptor D2 and Increases Pituitary Weight and Prolactin Production via Epigenetic Mechanisms.
Gangisetty O; Wynne O; Jabbar S; Nasello C; Sarkar DK
PLoS One; 2015; 10(10):e0140699. PubMed ID: 26509893
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in the pituitary transforming growth factor-β1 system: studies in a model of resistant prolactinomas.
Recouvreux MV; Lapyckyj L; Camilletti MA; Guida MC; Ornstein A; Rifkin DB; Becu-Villalobos D; Díaz-Torga G
Endocrinology; 2013 Nov; 154(11):4192-205. PubMed ID: 24008346
[TBL] [Abstract][Full Text] [Related]
19. New insights into the endocrine and metabolic roles of dopamine D2 receptors gained from the Drd2 mouse.
Garcia-Tornadú I; Perez-Millan MI; Recouvreux V; Ramirez MC; Luque G; Risso GS; Ornstein AM; Cristina C; Diaz-Torga G; Becu-Villalobos D
Neuroendocrinology; 2010; 92(4):207-14. PubMed ID: 20975260
[TBL] [Abstract][Full Text] [Related]
20. Pituitary prolactin-secreting tumor formation: recent developments.
Xu RK; Wu XM; Di AK; Xu JN; Pang CS; Pang SF
Biol Signals Recept; 2000; 9(1):1-20. PubMed ID: 10686432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
